Dear CTRMS Member,

The CTRMS Council is pleased to announce the start of the 2021 CTRMS Council Election. We encourage you to participate in the election to help determine your representatives for the CTRMS 2021-2025 term.

To be eligible to vote you must be Full, Allied Health or Emeritus Member of CTRMS.

To vote, please follow the steps below:

  1. Login into your account
  2. Click the button below and you will be taken to the election ballot.
  3. Prior to accessing the ballot you may view bios and photos on this page.
Deadline to vote:
Sunday May 16, 2021 at 23:59. EDT (Montreal time)

The future of the CTRMS depends upon your participation in this important decision-making process. The results of the election will be announced at the business meeting of the 2021 Joint Congress of IXA/CTRMS taking place on September 23-25, 2021.

Please visit our website

https://www.ixa-ctrms2021.org for more information.

Sincerely,

Maria Koulmanda
CTRMS Secretary

Nominees

Councilor Europe (Running Unopposed)
Fabio Marongiu

Fabio Marongiu is an Assistant Professor at the University of Cagliari. In 2003, he graduated with highest honors with an MS in Biological Sciences from University of Cagliari, and in 2007 he obtained his PhD from the same Institute in Chemotherapy of Viral Infections. In 2007 he was granted a fellowship for a 2-year post-doc at the University of Pittsburgh (USA) in the Department of Pathology under the supervision of Prof. Stephen Strom. The main topic of his research focused on the isolation, culture and characterization of human amnion-derived stem cells and their differentiation into other cell types. Since then he has maintained an active line of research on the regenerative medicine of the liver. His main contributions in the field pertain to the differentiation of amniotic cells into hepatocytes and other liver cell types, and their perspective use for the regeneration of the liver and the correction on inborn liver-based metabolic disease. In the last decade, his research interest has also focused on the role of tissue microenvironment in the development and progression of cancer, with particular regards to aging. These studies unveiled possible mechanistic links between carcinogenesis and tissue regenerations, with a specific focus on cell senescence and cell competition.

He has authored 49 peer reviewed articles in international Journals, 8 book chapters and over 30 contributions in international conferences, 7 of which were awarded for best presentation.

H-index: 21 (Scopus), 22 (Scholar) – Total Citations: 2026 (Scopus), 2984 (Scholar)

Councilor north america (one position)
Kim Solez
Kim Solez, MD, father of the Banff Classification, the Technology and Future of Medicine course LABMP590, the NEPHROL discussion group, and over 1500 YouTube videos, is often known as “the-Silicon-Valley-candidate” because of his close connection with the world of technology. He is a passionate advocate of the merging of the fields of transplantation and regenerative medicine, and use of AI to solve the big problems human beings cannot solve on their own. He has proposed a new Banff Classification of Tissue Engineering Pathology. Between semesters of the LABMP590 course he has traveled the world with The Future and All That Jazz initiative which incorporates regenerative medicine and artificial intelligence themes into an evening of poetry, music, and improvisation, and plans to release an album of this material in a year's time. He also serves as the co-chair of the Regenerative Medicine COP of the American Society of Transplantation which has just launched a new webinar series co-sponsored by the Tissue Engineering and Regenerative Medicine International Society (TERMIS); Kim was instrumental in the signing of a formal letter of agreement between the two societies with which they both recognize the need to join forces and build the future of transplant and regenerative medicine together.
Alicia Tomei

Dr. Tomei is an Assistant Professor in the departments of Biomedical Engineering, Immunology and Surgery and the director of the Islet Immunoengineering Laboratory at the Diabetes Research Institute at the University of Miami. She is applying her unique background in bioengineering and immunology to develop novel immunoengineering platforms to prevent rejection after islet transplantation and to promote antigen-specific tolerance for type-1 diabetes. Dr. Tomei holds a MS in Materials Engineering from the Politecnico of Milan (Italy) and a PhD in Bioengineering and Biotechnology from EPFL (Switzerland).

Dr. Tomei has received grants from the NIH, Iacocca Family Foundation, JDRF, Johnson & Johnson and Semma Therapeutics. She has presented her research work as invited speaker at the ADA, IPITA, BMES, TERMIS annual meetings. She has been a member of the JDRF beta cell replacement consortium since 2012, of the IPITA educational committee, and has served as grant reviewer for JDRF, CIRM, NIH, DoD. She was awarded the 2015 Marc S. Goodman Prize, the JDRF CDA and the Eliahu I. Jury Early Career Research Award in 2016, the 2018 Alexander Orr Excellence in Teaching Award, the 2019 Johnson A. Edosomwan Researcher of the Year Award, the 2020 Young Innovator in CMBE.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada